AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33528568 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 38
Study 33528568 — intervention group
Group type: COMPARATOR
Intervention: Non-COVID-19 patients
Number of subjects: 38
Study 33528632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented arthroplasty in elderly patients (older than 66.5 years)
Number of subjects: 25
Study 33528632 — intervention group
Group type: COMPARATOR
Intervention: Cemented arthroplasty in younger patients (younger than 66.5 years)
Number of subjects: 25
Study 33528632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented arthroplasty in young patients
Number of subjects: 25
Study 33528632 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented arthroplasty in elderly patients
Number of subjects: 25
Study 33528675 — intervention group
Group type: EXPERIMENTAL
Intervention: Karaduman Chewing Performance Scale (KCPS) assessment by pediatric dentists
Number of subjects: 97
Study 33528788 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative nausea and vomiting management
Number of subjects: 0
Study 33528788 — intervention group
Group type: EXPERIMENTAL
Intervention: Early self-rated quality of life
Number of subjects: 0
Study 33528792 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release fampridine (PR-FAM)
Number of subjects: 102
Study 33528850 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint Hypermobility Syndrome (JHS) in Functional Dyspepsia (FD)
Number of subjects: 54
Study 33528850 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient tolerance in JHS-FD
Number of subjects: 54
Study 33528850 — intervention group
Group type: COMPARATOR
Intervention: Non-JHS-FD
Number of subjects: 54
Study 33528867 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of glycolysis
Number of subjects: 0
Study 33528867 — intervention group
Group type: COMPARATOR
Intervention: Conditioned medium from cancer-associated fibroblasts (CAFs)
Number of subjects: 0
Study 33529058 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously once every 3 weeks for ≤ 24 months
Number of subjects: 165
Study 33529226 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic TMD
Number of subjects: 45
Study 33529485 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers for NAFLD (Steato-ELSA, Fatty Liver Index (FLI), Hepatic Steatosis Index (HSI), NAFLD-Liver Fat Score (NAFLD-LFS))
Number of subjects: 674
Study 33529485 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers for fibrosis (Fibrosis-4 score (FIB-4), Aspartate-to-Platelet Ratio Index (APRI), NAFLD Fibrosis Score (NFS))
Number of subjects: 674
Study 33529989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg intravenously once every 3 weeks, 2 cycles prior to surgery)
Number of subjects: 15
Study 33530135 — intervention group
Group type: EXPERIMENTAL
Intervention: High food responsiveness
Number of subjects: 92
Study 33530135 — intervention group
Group type: EXPERIMENTAL
Intervention: Low satiety responsiveness
Number of subjects: 92
Study 33530135 — intervention group
Group type: COMPARATOR
Intervention: Low food responsiveness
Number of subjects: 92
Study 33530695 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 160
Study 33530695 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health service use
Number of subjects: 160
Study 33530695 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid anxiety
Number of subjects: 160
Study 33530929 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness practice
Number of subjects: 475
Study 33530929 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness (FFMQ total score)
Number of subjects: 475
Study 33530929 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants scoring 7 or more on the stress scale
Number of subjects: 475
Study 33530929 — intervention group
Group type: EXPERIMENTAL
Intervention: Average level of mindfulness
Number of subjects: 475
Study 33530929 — intervention group
Group type: EXPERIMENTAL
Intervention: Average score of stress at work
Number of subjects: 475
Study 33530933 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitivity troponin T (hs-TNT)
Number of subjects: 739
Study 33530933 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitivity-C reactive protein (hs-CRP)
Number of subjects: 739
Study 33530933 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 739
Study 33530933 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro b-type natriuretic peptide (NT-proBNP)
Number of subjects: 739
Study 33530933 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein-cholesterol (HDL-C)
Number of subjects: 739
Study 33530933 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of biomarkers with clinical risk factors
Number of subjects: 739
Study 33531418 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide treatment
Number of subjects: 0
Study 33531437 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistently sufficient levels of 25(OH)D
Number of subjects: 679
Study 33531437 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing levels or temporary drop in 25(OH)D
Number of subjects: 679
Study 33531437 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary drop in 25(OH)D
Number of subjects: 679
Study 33531437 — intervention group
Group type: COMPARATOR
Intervention: Consistently deficient levels of 25(OH)D
Number of subjects: 679
Study 33531438 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 62512
Study 33531438 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 62512
Study 33531438 — intervention group
Group type: COMPARATOR
Intervention: Never use (control)
Number of subjects: 62512
Study 33531464 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol challenge test (specific dosage and duration not provided)
Number of subjects: 0
Study 33532807 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seropositivity testing
Number of subjects: 0
Study 33533507 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg QD on Days 1-5
Number of subjects: 16
Study 33533507 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3640254 200 mg QD on Days 1-7
Number of subjects: 16
Study 33533507 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg plus GSK3640254 200 mg QD on Days 1-7
Number of subjects: 16
Study 33533547 — intervention group
Group type: EXPERIMENTAL
Intervention: 2019 anti-HCV antibody prevalence
Number of subjects: 2326
Study 33533547 — intervention group
Group type: COMPARATOR
Intervention: 2012 anti-HCV antibody prevalence
Number of subjects: 2326
Study 33533547 — intervention group
Group type: EXPERIMENTAL
Intervention: 2019 HBsAg seropositivity
Number of subjects: 2326
Study 33533547 — intervention group
Group type: COMPARATOR
Intervention: 2012 HBsAg seropositivity
Number of subjects: 2326
Study 33533547 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-viremic rate in 2019
Number of subjects: 2326
Study 33533547 — intervention group
Group type: COMPARATOR
Intervention: HCV-viremic rate in 2012
Number of subjects: 2326
Study 33533547 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV treatment rate in 2019
Number of subjects: 2326
Study 33533547 — intervention group
Group type: COMPARATOR
Intervention: HCV treatment rate in 2012
Number of subjects: 2326
Study 33533547 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual incidence of new HCV
Number of subjects: 2326
Study 33533547 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg loss rate
Number of subjects: 2326
Study 33533547 — intervention group
Group type: EXPERIMENTAL
Intervention: New anti-HBc seropositivity rate
Number of subjects: 2326
Study 33533663 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-national collaboration in the ROCK-ALS trial
Number of subjects: 0
Study 33533729 — intervention group
Group type: EXPERIMENTAL
Intervention: XatJove Anoia mobile chat platform for health consultations
Number of subjects: 0
Study 33533729 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face consultations
Number of subjects: 0
Study 33533986 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized management of breakthrough cancer pain (BTcP) therapy
Number of subjects: 93
Study 33534046 — intervention group
Group type: COMPARATOR
Intervention: Locoregional surgery
Number of subjects: 1463
Study 33534229 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary breast cancer surgery within 12 months
Number of subjects: 1977
Study 33534229 — intervention group
Group type: COMPARATOR
Intervention: No surgery
Number of subjects: 1977
Study 33534266 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients admitted to Swedish ICUs
Number of subjects: 1563
Study 33534266 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1563
Study 33534266 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPS III score
Number of subjects: 1563
Study 33534266 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe respiratory failure
Number of subjects: 1563
Study 33534266 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific COVID-19 pharmacotherapy
Number of subjects: 1563
Study 33534266 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy
Number of subjects: 1563
Study 33534266 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of comorbidities (except chronic lung disease)
Number of subjects: 1563
Study 33534273 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking fatigability (WF) group (n=20, EDSS: 4.16 ± 1.41)
Number of subjects: 49
Study 33534273 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-walking fatigability group (n=29, EDSS: 2.62 ± 1.94)
Number of subjects: 49
Study 33534273 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 49
Study 33534419 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) guided treatment
Number of subjects: 0
Study 33534506 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART Pathway implementation
Number of subjects: 3370
Study 33534885 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine candidate (TAK-003)
Number of subjects: 0
Study 33535013 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive low-glucose suspend (PLGS) system
Number of subjects: 10
Study 33535013 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin suspension during overnight basal up-titration
Number of subjects: 10
Study 33535600 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibition as primary adjuvant therapy
Number of subjects: 1
Study 33535772 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33535773 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigator-reported (IR) triggers
Number of subjects: 2636
Study 33535773 — intervention group
Group type: COMPARATOR
Intervention: Non-investigator-reported (non-IR) triggers
Number of subjects: 2636
Study 33535773 — intervention group
Group type: EXPERIMENTAL
Intervention: IR myocardial infarction events
Number of subjects: 2636
Study 33535773 — intervention group
Group type: EXPERIMENTAL
Intervention: IR bleeding events
Number of subjects: 2636
Study 33535773 — intervention group
Group type: EXPERIMENTAL
Intervention: IR stroke events
Number of subjects: 2636
Study 33535773 — intervention group
Group type: EXPERIMENTAL
Intervention: IR stent thrombosis events
Number of subjects: 2636
Study 33535797 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic pain severity
Number of subjects: 370
Study 33535797 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary symptom severity
Number of subjects: 370
Study 33535797 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary frequency
Number of subjects: 370
Study 33535797 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpelvic pain severity
Number of subjects: 370
Study 33535799 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic Endoscopic Evaluation (cystoscopy and tissue sampling)
Number of subjects: 61
Study 33536021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous selexipag
Number of subjects: 20
Study 33536034 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-limb prosthesis
Number of subjects: 5
Study 33536034 — intervention group
Group type: COMPARATOR
Intervention: Prosthetic simulator (Control group)
Number of subjects: 5
Study 33536130 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride treatment for 4 weeks
Number of subjects: 387
Study 33536430 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound (MRgFUS) with intravenous microbubble administration
Number of subjects: 5
Study 33536430 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound (MRgFUS)
Number of subjects: 5
Study 33536740 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light with Meibomian Gland Expression (IPL-MGX)
Number of subjects: 20
Study 33536740 — intervention group
Group type: COMPARATOR
Intervention: Meibomian Gland Expression (MGX)
Number of subjects: 20
Study 33536791 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-professional medication reviews (MRs)
Number of subjects: 369
Study 33536791 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 369
Study 33536998 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle simulator training, details on dosage and duration not available
Number of subjects: 0
Study 33536998 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33537184 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Primary Schools of the Future (HPSF)
Number of subjects: 1647
Study 33537184 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Schools (PAS)
Number of subjects: 1647
Study 33537184 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 1647
Study 33537232 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with FLOT regimen (fluorouracil, leucovorin, oxaliplatin, and docetaxel) for four cycles.
Number of subjects: 10
Study 33537232 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with FLOT regimen for four cycles.
Number of subjects: 10
Study 33537232 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) and relapse-free survival (RFS) outcomes after treatment.
Number of subjects: 10
Study 33537339 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with Short Bowel Syndrome (SBS)
Number of subjects: 199
Study 33537564 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose subcutaneous sterile water injection
Number of subjects: 0
Study 33537564 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous saline injection
Number of subjects: 0
Study 33537575 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity smoking cessation intervention (n=42)
Number of subjects: 84
Study 33537575 — intervention group
Group type: COMPARATOR
Intervention: Minimal contact control group (n=42)
Number of subjects: 84
Study 33537757 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically unhealthy obese (MUHO) with T2D
Number of subjects: 112
Study 33537757 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese men with T2D
Number of subjects: 112
Study 33537757 — intervention group
Group type: COMPARATOR
Intervention: Metabolically healthy obese (MHO)
Number of subjects: 112
Study 33537757 — intervention group
Group type: COMPARATOR
Intervention: Metabolically unhealthy obese (MUHO) without T2D
Number of subjects: 112
Study 33537757 — intervention group
Group type: COMPARATOR
Intervention: Obese men without T2D
Number of subjects: 112
Study 33537947 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antithrombotic management patterns in patients with eGFR < 60 mL/min/1.73 m²
Number of subjects: 22380
Study 33537956 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 23
Study 33538517 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release carbidopa/levodopa (IR)
Number of subjects: 0
Study 33538517 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release carbidopa/levodopa (CR)
Number of subjects: 0
Study 33538517 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa/entacapone (CLE)
Number of subjects: 0
Study 33538517 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in levodopa equivalent daily dose
Number of subjects: 0
Study 33538517 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment
Number of subjects: 0
Study 33538517 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's Disease Questionnaire mobility subscore
Number of subjects: 0
Study 33538517 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwab and England Activities of Daily Living Scale
Number of subjects: 0
Study 33538517 — intervention group
Group type: EXPERIMENTAL
Intervention: Global composite outcome
Number of subjects: 0
Study 33538649 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health (mHealth) intervention called MOCT
Number of subjects: 60
Study 33538700 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound before laparoscopic cholecystectomy
Number of subjects: 106
Study 33538700 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative cholangiography during laparoscopic cholecystectomy
Number of subjects: 106
Study 33538700 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound and endoscopic retrograde cholangiography on demand
Number of subjects: 106
Study 33538700 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative cholangiography
Number of subjects: 106
Study 33538700 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiography on demand
Number of subjects: 106
Study 33538700 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound
Number of subjects: 106
Study 33538700 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiography
Number of subjects: 106
Study 33538700 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound, intraoperative cholangiography, and endoscopic retrograde cholangiography
Number of subjects: 106
Study 33538699 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health and self-management app (8-week program including Lung Attack Action Plan, education, medication overview, video consultation, and questionnaires)
Number of subjects: 39
Study 33538699 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health and self-management app
Number of subjects: 39
Study 33538761 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone Iodine Mouthwash, Gargle, and Nasal Spray
Number of subjects: 0
Study 33538797 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus R-CHOP
Number of subjects: 206
Study 33538797 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (control group from GOYA/BO21005 study)
Number of subjects: 206
Study 33538996 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate/formoterol fumarate (BDP/FF) NEXThaler
Number of subjects: 43
Study 33539138 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based symptom management program (My MS toolkit)
Number of subjects: 0
Study 33539138 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33539145 — intervention group
Group type: EXPERIMENTAL
Intervention: self/group-therapist alliance dimension
Number of subjects: 165
Study 33539145 — intervention group
Group type: EXPERIMENTAL
Intervention: other-therapist alliance dimension
Number of subjects: 165
Study 33539145 — intervention group
Group type: EXPERIMENTAL
Intervention: within-system alliance dimension
Number of subjects: 165
Study 33539144 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders
Number of subjects: 54
Study 33539543 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze all strategy
Number of subjects: 4712
Study 33539543 — intervention group
Group type: COMPARATOR
Intervention: Conventional IVF/ICSI strategy
Number of subjects: 4712
Study 33539561 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-exergames
Number of subjects: 468
Study 33539561 — intervention group
Group type: COMPARATOR
Intervention: Cognitive remediation
Number of subjects: 468
Study 33539561 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergames
Number of subjects: 468
Study 33539714 — intervention group
Group type: EXPERIMENTAL
Intervention: Trexo Home robotic gait trainer
Number of subjects: 1
Study 33539743 — intervention group
Group type: EXPERIMENTAL
Intervention: 55 Gy in 20 fractions
Number of subjects: 782
Study 33539743 — intervention group
Group type: COMPARATOR
Intervention: 64 Gy in 32 fractions
Number of subjects: 782
Study 33539762 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring (DVR)
Number of subjects: 1456
Study 33539837 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Vital Capacity (SVC)
Number of subjects: 854
Study 33539837 — intervention group
Group type: COMPARATOR
Intervention: Forced Vital Capacity (FVC)
Number of subjects: 854
Study 33540481 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 0
Study 33540481 — intervention group
Group type: EXPERIMENTAL
Intervention: Latency reversal agents
Number of subjects: 0
Study 33540485 — intervention group
Group type: EXPERIMENTAL
Intervention: DalcA (subcutaneous 150 IU/kg daily for 6 days)
Number of subjects: 11
Study 33540485 — intervention group
Group type: COMPARATOR
Intervention: DalcA (intravenous 75 IU/kg)
Number of subjects: 11
Study 33540485 — intervention group
Group type: EXPERIMENTAL
Intervention: DalcA (subcutaneous 75 IU/kg)
Number of subjects: 11
Study 33540485 — intervention group
Group type: EXPERIMENTAL
Intervention: DalcA (subcutaneous 150 IU/kg)
Number of subjects: 11
Study 33540485 — intervention group
Group type: COMPARATOR
Intervention: BeneFIX (intravenous 75 IU/kg)
Number of subjects: 11
Study 33541097 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve intervention
Number of subjects: 300
Study 33541106 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical risk
Number of subjects: 13172
Study 33541106 — intervention group
Group type: COMPARATOR
Intervention: Procedural risk
Number of subjects: 13172
Study 33541106 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 13172